Some of these promising treatments such as CD19 CAR T cells treatments are now part of regular treatment options for refractory patients with B-acute lymphoblastic leukemia (ALL), diffuse large B cell lymphoma, mantle cell lymphoma, or follicular lymphoma. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.